Oncology News | pharmaphorum

News

Ex-Merck & Co scientist accused of stealing trade secrets co...

A former Merck & Co scientist could face up to 10 years in prison after he was accused of stealing trade secrets relating to drugs including the cancer immunotherapy Keytruda by US auth

News

AZ/Daiichi Sankyo's Enhertu gets second US cancer indication

AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab).

News

IO Biotech raises $155m to develop breakthrough cancer vacci...

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted eff

News

Boehringer Ingelheim, Biberach, Germany, February 2007

BI investigates cancer 'dark antigens' with UK's Enara

Boehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight cancer using “dark antigens” in a deal worth up to €876 million ($1.07b

News

bluebird bio to split into oncology and gene therapy special...

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning off as the company prepares to bring its products to market.

News

Oxford BioTherapeutics to research cell therapies for Gilead...

Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch of cell therapy products for solid tumours and blood cancers.

Ex-Merck & Co scientist accused of stealing trade secrets co...

AZ/Daiichi Sankyo's Enhertu gets second US cancer indication

IO Biotech raises $155m to develop breakthrough cancer vacci...

BI investigates cancer 'dark antigens' with UK's Enara

bluebird bio to split into oncology and gene therapy special...

Oxford BioTherapeutics to research cell therapies for Gilead...

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks